Jennison Associates
MYGN icon

Jennison Associates’s Myriad Genetics MYGN Stock Holding History

Jennison Associates’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60,811
Closed -$539K – 620
2025
Q1 		$539K Buy
60,811
+1,796
+3% +$21.6K ﹤0.01% 547
2024
Q4 		$809K Buy
59,015
+34,853
+144% +$643K ﹤0.01% 510
2024
Q3 		$662K Buy
+24,162
New +$654K ﹤0.01% 531
2019
Q1 		– Sell
-16,388
Closed -$476K – 674
2018
Q4 		$476K Sell
16,388
-1,069
-6% -$38.5K ﹤0.01% 621
2018
Q3 		$803K Sell
17,457
-11,147
-39% -$496K ﹤0.01% 571
2018
Q2 		$1.07M Buy
28,604
+613
+2% +$20.7K ﹤0.01% 564
2018
Q1 		$827K Buy
+27,991
New +$947K ﹤0.01% 571

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jennison Associates's MYGN Position: Q2 2025 in Review

Jennison Associates sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 60,811 shares — an estimated $539K sold.

Jennison Associates first reported a position in MYGN in Q1 2018 and held it in 7 quarters. The position peaked at $1.07M in Q2 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Jennison Associates reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Jennison Associates sold 60,811 Myriad Genetics shares in Q2 2025, an estimated $539K.
  • Jennison Associates first reported a position in Myriad Genetics in Q1 2018 and held it in 7 quarters.
  • Jennison Associates's Myriad Genetics position peaked at $1.07M in Q2 2018.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.